Although darapladib, a potent Lp-PLA2 inhibitor, failed to meet the primary endpoints of two large phase III trials for treatment of atherosclerosis [181], recent clinical and preclinical studies have revealed that Lp-PLA2 inhibition may have therapeutic effects in diabetic macular edema and Alzheimer’s disease [182,183]. Here, PLA2G7 is linked to diabetic macular edema.